Olmesartan Medoxomil/Amlodipine Besylate/Hydrochlorothiazide

奥美沙坦酯/苯磺酸氨氯地平/氢氯噻嗪

Report date: 2023/06/25 14:34:55

Base Information

Drug NameOlmesartan Medoxomil/Amlodipine Besylate/Hydrochlorothiazide
Drug Alias NameAmlodipine Besylate/Hydrochlorothiazide/Olmesartan Medoxomil氢氯噻嗪/苯磺酸氨氯地平/奥美沙坦酯苯磺酸氨氯地平/奥美沙坦酯/氢氯噻嗪Hydrochlorothiazide/Olmesartan Medoxomil/Amlodipine BesylateOlmesartan medoxomil - amlodipine besylate - hydrochlorothiazide mixt +[8] 
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsVoltage-gated calcium channel blockersThiazide-sensitive sodium-chloride cotransporter inhibitors
TargetsThiazide-sensitive sodium-chloride cotransporterAngiotensin II Receptor Type 1Voltage-gated calcium channel
Therapy Area/IndicationsEssential HypertensionHypertension
Global Approved IndicationsHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2010/07/23
Country/TerritoryCzechiaBelgiumBulgaria +[18] 
CombinationsYes HydrochlorothiazideAmlodipine BesylateOlmesartan Medoxomil
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDaiichi Sankyo Co LtdShanghai Tenry Pharmaceutical Co LtdGuangzhou Bositao Controlled Release Pharmaceutical Co Ltd
Inactive CompaniesDaiichi Sankyo Korea Co Ltd
Active IndicationsHypertension
Inactive IndicationsEssential Hypertension

Other Information

ATC CodeC09DX03
Related LinksKEGG